論文ID: 2026-0067
Although vestibular schwannomas are common, benign intracranial tumors with similar histopathology originating from other nerves are rare. For non-vestibular schwannomas, surgery remains standard treatment, albeit associated with morbidities. Radiotherapy offers a safe and effective alternative treatment modality. Nevertheless, the previous publication had a limited follow-up period and included outcomes from both stereotactic radiosurgery and radiotherapy. To investigate our long-term results, a retrospective chart review was conducted in patients who received stereotactic radiotherapy for non-vestibular schwannomas using hypo- or conventional fractionated regimen, from 2000 to 2020, with a minimum follow-up of 24 months. Treatment failure was defined as a ≥20% tumor growth, necessitating additional treatment. Radiation-induced sequelae were also observed. During the study period, 66 patients underwent stereotactic radiotherapy for non-vestibular schwannomas. After excluding non-eligible cases, 57 patients were analyzed. The tumor's median volume was 6.5 milliliters (interquartile range 2.85-11.04). Hypofractionated stereotactic radiotherapy, delivered in 3, 5, or 10 sessions, was used in 53 patients, while 4 patients received 25-day conventional fractionated stereotactic radiotherapy. With a median follow-up of 121 months (interquartile range 54-159), tumor control was achieved in 55 subjects (96.5%), with surgical resection necessary in 2 patients after radiation. The actuarial control rates were 100%, 97%, and 92% at 5, 10, and 15 years, respectively. Tumor shrinkage was observed in 27 individuals (47.37%). Regarding complications, one patient reported worsening of facial numbness after radiation. With extended follow-up compared to prior reports, our long-term outcomes support the efficacy and safety of hypo- and conventional fractionated stereotactic radiotherapy for non-vestibular schwannomas.
